The Board of Elan Corporation, plc ELN (the Company) acknowledges this
morning's announcement by Royalty Management, LLC (Royalty Pharma) regarding
an indicative, conditional, proposal which may or may not lead to an offer
being made for the entire issued share capital of the Company.
As previously announced, in anticipation of executing and closing the recently
announced Tysabri transaction, the Company's Board of Directors, Executive
Management and advisors have been working for over a year on a number of
strategic transactions that, should they be consummated, would be to the
benefit of our public shareholders. Returning capital through share
repurchase, diversifying business and asset risk/reward through
non-traditional business structures while simultaneously capturing the long
term high margin royalty income from Tysabri will offer a compelling
investment thesis for our current shareholders.
The Company notes the highly opportunistic timing of the announcement by
Royalty Pharma - a privately held investment management company - before the
Company's shareholders have had the opportunity to assess and realize the full
benefit of the Tysabri transaction and the partial unlocking of its value. We
expect the Tysabri transaction to close in the near future.
The Company also notes the heavily conditional nature of this indication of
interest. Any credible proposal which may be made by Royalty Pharma or any
other party will of course be considered by the Company alongside the
strategic transactions and unique investment thesis referred to above.
Further announcements will be made if and when appropriate.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in